Labrys Biologics Seals $31M Series A
Labrys Biologics, a company developing treatments for chronic migraines, has raised a $31 million Series A financing. VenBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures all participated in the round. The money helps Labrys acquire the worldwide rights to the RN-307 antibody from Pfizer Inc.
3 January 2013•3 mins read
